Inglis Tiffany Eul Davis Sells Shares of SERA $SERA
Key Points
- Inglis Tiffany Eul Davis sold 362 shares of Sera Prognostics, Inc. ($SERA) worth $728.
- $SERA last traded around $1.91.
Inglis Tiffany Eul Davis, Chief Medical Officer at Sera Prognostics, Inc. ($SERA), sold 362 shares at an average price of $2.01, for a total transaction of $728. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Sera Prognostics, Inc. ($SERA) Stock
Sera Prognostics, Inc. Earnings
Analysts Set New Price Targets
About Sera Prognostics, Inc.
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.